NAS:CRVS (USA) Also Trade In: Germany
Corvus Pharmaceuticals Inc $ 3.93 -0.16 (-3.91%)
Warning! GuruFocus has detected 1 Severe warning sign with CRVS. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Corvus Pharmaceuticals Inc () from 2016 to Sep 30 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Corvus Pharmaceuticals stock (CRVS) PE ratio as of Sep 30 2020 is 0. More Details
Corvus Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Corvus Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare OTCPK:HGEN NAS:GLMD NAS:CWBR AMEX:PTN NAS:CLSD NAS:EYPT NAS:CSBR NAS:CATB AMEX:PLX NAS:MRKR OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing small-molecule and antibody agents that target the immune system to treat patients with cancer. The firm's pipeline includes CPI-006, CPI-818, CPI-935, and others.